Guggenheim reiterated their buy rating on shares of Foamix Pharmaceuticals (NASDAQ:FOMX) in a research note published on Thursday. They currently have a $8.00 price target on the specialty pharmaceutical company’s stock.

FOMX has been the topic of several other research reports. HC Wainwright began coverage on shares of Foamix Pharmaceuticals in a report on Thursday, August 24th. They issued a buy rating and a $12.00 target price on the stock. Zacks Investment Research raised shares of Foamix Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, November 29th.

Foamix Pharmaceuticals (NASDAQ:FOMX) traded down $0.02 during midday trading on Thursday, reaching $5.94. 58,700 shares of the company’s stock were exchanged, compared to its average volume of 156,830. Foamix Pharmaceuticals has a one year low of $4.03 and a one year high of $11.27.

Foamix Pharmaceuticals (NASDAQ:FOMX) last issued its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.03). The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $0.90 million. Foamix Pharmaceuticals had a negative net margin of 1,439.32% and a negative return on equity of 54.81%. The firm’s revenue was down 64.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.19) EPS. equities research analysts anticipate that Foamix Pharmaceuticals will post -1.34 EPS for the current year.

Several large investors have recently modified their holdings of FOMX. Renaissance Technologies LLC purchased a new stake in shares of Foamix Pharmaceuticals in the first quarter valued at about $307,000. Bank of New York Mellon Corp boosted its holdings in Foamix Pharmaceuticals by 38.6% during the second quarter. Bank of New York Mellon Corp now owns 544,853 shares of the specialty pharmaceutical company’s stock worth $2,528,000 after buying an additional 151,849 shares in the last quarter. Marshall Wace North America L.P. boosted its holdings in Foamix Pharmaceuticals by 42.7% during the second quarter. Marshall Wace North America L.P. now owns 632,819 shares of the specialty pharmaceutical company’s stock worth $3,164,000 after buying an additional 189,350 shares in the last quarter. AXA boosted its holdings in Foamix Pharmaceuticals by 14.1% during the second quarter. AXA now owns 942,735 shares of the specialty pharmaceutical company’s stock worth $4,374,000 after buying an additional 116,298 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its holdings in Foamix Pharmaceuticals by 1.6% during the second quarter. UBS Asset Management Americas Inc. now owns 106,312 shares of the specialty pharmaceutical company’s stock worth $493,000 after buying an additional 1,633 shares in the last quarter. 57.43% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/15/foamix-pharmaceuticals-fomx-given-buy-rating-at-guggenheim.html.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.